Get Fit Bharat

Tag: Tips

HomeTips

Third quarter 2024 highlights (All comparisons to corresponding period in 2023) •          Order intake of USD 143.9 million, -5.1% YoY and on par QoQ •          Revenue of USD 144.2 million, slightly ahead of expectations communicated at recent Capital Markets Day •          2024 revenue guidance remains unchanged at USD 575-600 million …

Westbury, N.Y., United States:  BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced an exclusive agreement* with KRISHGEN BioSystems, a leading provider of life science research tools and services for over two decades in India, Bangladesh and Nepal. KRISHGEN BioSystems’ long-standing experience and strong …

FIDELITY CHINA SPECIAL SITUATIONS PLC (the 'Company')     TRANSACTION IN OWN SHARES     The Board of the Company announces that it has repurchased for cancellation.     Number of shares repurchased: 230,000 Date of transaction: 06 November 2024 Average share price paid per share (GBp): 214.230 Lowest share price paid per share (GBp): …

FIDELITY JAPAN TRUST PLC (the 'Company')     TRANSACTION IN OWN SHARES     The Board of the Company announces that it has bought into Treasury     Number of shares repurchased: 30,321 Date of transaction: 06 November 2024 Average share price paid per share (GBp): 156.410 Lowest share price paid per share (GBp): 155.500 …

Hamilton, Bermuda, November 6, 2024: Borr Drilling Limited (“Borr”, “Borr Drilling” or the “Company”) announces unaudited results for the three and nine months ended September 30, 2024. Highlights Total operating revenues of $241.6 million, a decrease of $30.3 million or 11% compared to the second quarter of 2024 Net income of …

Hamilton, Bermuda, November 6, 2024. Borr Drilling Limited (NYSE and OSE: BORR) today announces that the Company’s Board of Directors has approved a cash distribution of paid-in capital of US$0.02 per share for the third quarter of 2024. Note to shareholders registered in Euronext VPS, the Norwegian Central Security Depository: …

  Oslo, Norway, November 6, 2024 - Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients …